ITGAX and acute myeloid leukemia: Treatment with ATRA both in these stably transfected PML-RARα expressing U937 cells as well as in t(15;17)-carrying human AML cells (NB4) led to differentiation as verified by increased expression of myeloid markers such as CD11b and CD11c after 72 hours of treatment (S1 Fig).